At a glance
Effects
- Reduction of thyroid hormones (T3 & T4): Blocks thyroid peroxidase-mediated synthesis of T3 and T4, progressively lowering circulating thyroid hormone levels and restoring euthyroid (normal) thyroid status [2].
- Relief of hyperthyroid symptoms: As hormone levels normalise, symptoms such as rapid heart rate, excessive sweating, nervousness, heat intolerance, and tremor are progressively alleviated [4].
- Pre-surgical / pre-radioiodine thyroid control: Used to render a hyperthyroid patient euthyroid before thyroidectomy or radioactive iodine treatment, reducing surgical and anaesthetic risk [6].
- Possible immunomodulation in Graves' disease: Some evidence suggests a secondary immunomodulatory effect reducing thyroid-stimulating antibodies, though it is unclear if this is direct or secondary to lower thyroid hormone levels [5].
Thionamide antithyroid agent
4–6 hours (oral)
Oral (tablet)
Gradual; 2–4 weeks as pre-formed hormones deplete
Prescription only — not a controlled substance
About Methimazole
Every point here is drawn from public medical and harm-reduction sources. A bracketed number after a claim — like [1]— is a reference: tap it to open the exact source it's based on (numbered list at the bottom). It is not a rating or score. Educational information, not medical advice.
Product specifics
- Est. delivery
- 3–7 business days · EU tracked
Product details as stated by the vendor (claims, not independently verified). Delivery is our standard EU estimate.
What it is
Methimazole (brand name Tapazole) is a thionamide antithyroid drug used to treat hyperthyroidism — the medical condition where the thyroid gland produces excessive thyroid hormones [1]. It is the primary oral antithyroid agent used in the United States for conditions such as Graves' disease, toxic multinodular goiter, and pre-surgical thyroid preparation [2].
How it works
Methimazole works by potently inhibiting thyroid peroxidase (TPO), the enzyme responsible for iodinating tyrosine residues on thyroglobulin — a key step in manufacturing the thyroid hormones T3 and T4 [2][3]. By blocking this enzymatic process, methimazole halts new hormone synthesis; however, it does not destroy pre-formed hormones already stored in or circulating from the thyroid, so clinical improvement is gradual (typically 2–4 weeks) as existing hormones are naturally depleted [4]. It is rapidly absorbed from the gastrointestinal tract, reaching peak serum concentration within 1–2 hours, and its thionamide structure allows it to bind irreversibly to TPO at its active site [5][3].
Risks & side effects
Most important: Agranulocytosis — a potentially life-threatening drop in white blood cell count — is the most critical risk; it can occur at any dose or duration of treatment and may develop rapidly, particularly in the first two months and in patients over 40 or taking doses above 40 mg/day [7]. Any fever, sore throat, mouth ulcers, or unusual bruising requires immediate medical attention and a CBC; do not attempt to self-treat these symptoms [4].
Common
Serious
- Agranulocytosis (rapid fall in white blood cells — seek emergency care for fever or sore throat) [7]
- Hypothyroidism / over-treatment causing thyroid hormone deficiency [3]
- Liver damage / cholestatic jaundice (dark urine, right-upper abdominal pain, jaundice) [8]
- Thrombocytopenia and hypoprothrombinemia / bleeding risk [6]
- Hypoglycaemia (low blood sugar) [8]
- Vasculitis [8]
Safety & harm reduction
- Known hypersensitivity or allergy to methimazole or any component of the formulation [3]
- First trimester of pregnancy — associated with rare but serious congenital malformations; PTU preferred [6]
- Breastfeeding (use only under close medical supervision; drug passes into breast milk) [6]
- Pre-existing severe hepatic disease without specialist oversight [9]
- Thyroid function tests (TSH, free T4) — monthly during initial therapy, then every 2–3 months [7]
- Complete blood count (CBC) with differential — baseline and every 2 weeks for first 3 months to detect agranulocytosis [10]
- Liver function tests (AST, ALT, bilirubin) — periodically; discontinue if transaminases exceed 3× upper limit of normal [7]
- Prothrombin time / INR — especially if co-administered with warfarin or before any surgical procedure [6]
- Digoxin serum levels — monitor closely as thyroid function normalises; dose reduction of ~30–40% may be required [10]
- Warfarin / oral anticoagulants — methimazole potentiates anticoagulant effect by inhibiting vitamin K activity; close INR monitoring and dose adjustment required [6]
- Digoxin — methimazole may raise digoxin serum concentrations as thyroid function normalises, increasing risk of digitalis toxicity [3]
- Theophylline — clearance decreases as hyperthyroidism is corrected; reduce theophylline dose by ~25–30% and monitor levels [3]
- Lithium — methimazole may increase lithium serum concentration, elevating risk of lithium toxicity (tremor, ataxia, seizures) [3]
- Beta-blockers — clearance of high-extraction beta-blockers may change as thyroid status normalises; monitor and adjust accordingly [6]
- Drugs causing agranulocytosis (e.g. clozapine, carbamazepine, sulfasalazine) — additive risk; extreme caution and enhanced CBC monitoring required [10]
- Administer at the same time(s) each day relative to food to maintain consistent blood levels [2]
- Initiate at higher doses (15–60 mg/day divided into three doses 8 hours apart) to achieve euthyroid state, then reduce maintenance dose by approximately 50% for long-term therapy (typically 12–18 months) [6]
- Immediately discontinue and seek medical evaluation if fever, sore throat, mouth ulcers, or unusual bruising develop — possible agranulocytosis [4]
- Discontinue on the day of thyroid surgery as directed by the treating physician [1]
- If hypothyroidism develops during treatment (rising TSH), reduce dose promptly under medical guidance [6]
Dosage context
Commonly reported adult dosing (not a prescription; always follow prescriber guidance): initial doses of 15–60 mg/day divided into three doses taken 8 hours apart, depending on severity of hyperthyroidism [6]; once euthyroid state is achieved, maintenance is typically reduced by ~50% to 5–15 mg/day for 12–18 months [6]. For mild-to-moderate hyperthyroidism, starting doses of 10–20 mg/day are commonly used [6]. Sources differ and individual requirements vary considerably — dosing must be guided by thyroid function monitoring.
Sources
- 1.DrugBank — Methimazole
- 2.Patsnap Synapse — Methimazole Uses & Mechanism
- 3.StatPearls / NCBI — Methimazole (NBK545223)
- 4.VHTC — Antithyroid Drugs Review
- 5.ScienceDirect Topics — Methimazole Overview
- 6.RxList — Tapazole (Methimazole) Full Prescribing Information
- 7.Davis's Drug Guide — Methimazole
- 8.Drugs.com — Methimazole Uses, Side Effects & Warnings
- 9.Drugs.com — Methimazole / Warfarin Interaction
- 10.DrOracle — Methimazole Drug Interactions (warfarin, digoxin, theophylline)
- 11.FDA DailyMed — Methimazole Tablets Label
- 12.StatPearls Point of Care — Methimazole
This information is provided for educational and harm-reduction purposes only. It is not medical advice. These substances can carry serious health risks; effects and safe use vary by individual. Consult a qualified healthcare professional before use. Legal status varies by country — it is your responsibility to know your local law. We do not encourage misuse.